Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Stock Has Consensus Target Price of $15.62

Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) has received a consensus rating of “Hold” from the five research firms that are currently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and three have assigned a buy recommendation to the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $15.62.

Several research analysts have recently weighed in on the stock. Wall Street Zen raised shares of Adial Pharmaceuticals to a “sell” rating in a research report on Saturday, August 15th. Loop Capital set a $6.00 price target on shares of Adial Pharmaceuticals in a research note on Monday, June 15th. Weiss Ratings upgraded shares of Adial Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday. Needham & Company LLC downgraded Adial Pharmaceuticals to a “buy” rating in a report on Monday, June 15th. Finally, Alliance Global Partners started coverage on Adial Pharmaceuticals in a research report on Monday, August 3rd. They issued a “buy” rating and a $11.00 price objective for the company.

Adial Pharmaceuticals Price Performance

Shares of ADIL stock opened at $4.22 on Wednesday. The company’s fifty day moving average price is $4.73 and its two-hundred day moving average price is $3.01. The firm has a market capitalization of $11.10 million, a P/E ratio of -0.29 and a beta of 1.38. Adial Pharmaceuticals has a 12 month low of $1.31 and a 12 month high of $10.75.

Adial Pharmaceuticals (NASDAQ:ADIL) last issued its earnings results on Friday, August 14th. The company reported ($11.25) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.03) by ($10.22).

Insider Buying and Selling

In other Adial Pharmaceuticals news, major shareholder Coastlands Capital Lp acquired 10,053 shares of Adial Pharmaceuticals stock in a transaction dated Thursday, July 9th. The stock was bought at an average cost of $2.79 per share, for a total transaction of $28,047.87. Following the purchase, the insider directly owned 383,375 shares in the company, valued at approximately $1,069,616.25. This represents a 2.69% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this link. Over the last quarter, insiders have bought 36,753 shares of company stock worth $97,638. Insiders own 8.00% of the company’s stock.

About Adial Pharmaceuticals

Adial Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing treatments for addiction and related disorders. The company’s primary focus is alcohol use disorder, a chronic condition characterized by problematic alcohol consumption and difficulty reducing or stopping use.

Adial’s lead investigational product, AD04, is an oral, genetically targeted therapy based on ondansetron, a selective serotonin-3 receptor antagonist. The company is studying AD04 as a potential treatment for alcohol use disorder in patients identified through genetic or biomarker-based testing.